Stephens analyst Steven Etoch resumed coverage of Bio-Techne (TECH) with an Overweight rating and $65 price target The firm says the company through acquisitions has a “high-quality” recurring-revenue life science tools platform. The shares are down 27% year-to-date, creating Bio-Techne’s lowest valuation since 2017, on “transitory headwinds” tied to government and academic funding concerns, the analyst tells investors in a research note. Stephens is constructive on the company’s exposure to secular growth themes in diagnostics and cell and gene therapy.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TECH:
- Bio-Techne and Spear Bio partner for ultrasensitive biomarker detection
- Bio-Techne initiated with a Buy at TD Cowen
- Bio-Techne: Undervalued Stock with Strong Growth Potential and Margin Expansion Opportunities
- Bio-Techne, USP collaborate to develop monoclonal antibody and gene therapy
- Airbnb, Zscaler downgraded: Wall Street’s top analyst calls